

Karen A Gelmon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9149634/publications.pdf>

Version: 2024-02-01

89
papers

10,023
citations

117453

34
h-index

64668

79
g-index

89
all docs

89
docs citations

89
times ranked

13069
citing authors

#	ARTICLE	IF	CITATIONS
1	Palbociclib and Letrozole in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 1925-1936.	13.9	1,943
2	Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. <i>Lancet Oncology</i> , 2011, 12, 852-861.	5.1	1,028
3	Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 597-609.	13.9	789
4	Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. <i>New England Journal of Medicine</i> , 2021, 384, 2394-2405.	13.9	764
5	Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. <i>Nature</i> , 2015, 518, 422-426.	13.7	545
6	Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. <i>New England Journal of Medicine</i> , 2016, 375, 209-219.	13.9	507
7	Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 2610-2619.	0.8	331
8	Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel. <i>Journal of Clinical Oncology</i> , 2003, 21, 3965-3971.	0.8	286
9	Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers. <i>Journal of Clinical Oncology</i> , 2008, 26, 5697-5704.	0.8	260
10	Randomized Phase II Study of BR96-Doxorubicin Conjugate in Patients With Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 1999, 17, 478-478.	0.8	243
11	Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes. <i>JAMA Oncology</i> , 2016, 2, 751.	3.4	243
12	Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27—A Randomized Controlled Phase III Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 1398-1404.	0.8	218
13	Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. <i>Breast Cancer Research and Treatment</i> , 2011, 126, 215-220.	1.1	170
14	Clonal Decomposition and DNA Replication States Defined by Scaled Single-Cell Genome Sequencing. <i>Cell</i> , 2019, 179, 1207-1221.e22.	13.5	162
15	Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31. <i>Journal of Clinical Oncology</i> , 2015, 33, 1574-1583.	0.8	146
16	Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 7521-7530.	3.2	144
17	Comparison of Breast Cancer Recurrence and Outcome Patterns Between Patients Treated From 1986 to 1992 and From 2004 to 2008. <i>Journal of Clinical Oncology</i> , 2015, 33, 65-73.	0.8	131
18	Pegylated Liposomal Doxorubicin and Trastuzumab in HER-2 Overexpressing Metastatic Breast Cancer: A Multicenter Phase II Trial. <i>Journal of Clinical Oncology</i> , 2006, 24, 2773-2778.	0.8	130

#	ARTICLE	IF	CITATIONS
19	Autophagy Inhibition Augments the Anticancer Effects of Epirubicin Treatment in Anthracycline-Sensitive and -Resistant Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 3159-3173.	3.2	126
20	Use of Trastuzumab Beyond Disease Progression: Observations from a Retrospective Review of Case Histories. <i>Clinical Breast Cancer</i> , 2004, 5, 52-58.	1.1	124
21	Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 110-121.	3.2	120
22	Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 141-148.	0.8	113
23	Effect of Metformin vs Placebo on and Metabolic Factors in NCIC CTG MA.32. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv006-djv006.	3.0	112
24	Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes. <i>Nature Cancer</i> , 2020, 1, 452-468.	5.7	103
25	Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer (ER+/HER2- ABC): Analyses from PALOMA-2. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA1003-LBA1003.	0.8	95
26	Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers. <i>Journal of Physical Education and Sports Management</i> , 2015, 1, a000570.	0.5	92
27	Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1963.	3.8	81
28	The effect of an aerobic exercise bout 24h prior to each doxorubicin treatment for breast cancer on markers of cardiotoxicity and treatment symptoms: a RCT. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 719-729.	1.1	67
29	Application of a Neural Network Whole Transcriptome-Based Pan-Cancer Method for Diagnosis of Primary and Metastatic Cancers. <i>JAMA Network Open</i> , 2019, 2, e192597.	2.8	67
30	Identification of breast cancer cell subtypes sensitive to ATG4B inhibition. <i>Oncotarget</i> , 2016, 7, 66970-66988.	0.8	58
31	Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection. <i>Cancer Chemotherapy and Pharmacology</i> , 1998, 41, 347-352.	1.1	48
32	Phase I Dose-Finding Study of a New Taxane, RPR 109881A, Administered as a One-Hour Intravenous Infusion Days 1 and 8 to Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2000, 18, 4098-4108.	0.8	48
33	Interval versus continuous aerobic exercise training in breast cancer survivors—a pilot RCT. <i>Supportive Care in Cancer</i> , 2016, 24, 119-127.	1.0	48
34	Effectiveness of Oncologist-Referred Exercise and Healthy Eating Programming as a Part of Supportive Adjuvant Care for Early Breast Cancer. <i>Oncologist</i> , 2018, 23, 105-115.	1.9	44
35	Effects of exercise dose and type during breast cancer chemotherapy on longer-term patient-reported outcomes and health-related fitness: A randomized controlled trial. <i>International Journal of Cancer</i> , 2020, 146, 150-160.	2.3	39
36	Base excision repair deficiency signatures implicate germline and somatic MUTHYH aberrations in pancreatic ductal adenocarcinoma and breast cancer oncogenesis. <i>Journal of Physical Education and Sports Management</i> , 2019, 5, a003681.	0.5	33

#	ARTICLE	IF	CITATIONS
37	“Chemotherapy-periodized” Exercise to Accommodate for Cyclical Variation in Fatigue. <i>Medicine and Science in Sports and Exercise</i> , 2020, 52, 278-286.	0.2	33
38	A Longitudinal Study of the Association of Clinical Indices of Cardiovascular Autonomic Function with Breast Cancer Treatment and Exercise Training. <i>Oncologist</i> , 2019, 24, 273-284.	1.9	28
39	A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer. <i>Breast Cancer Research</i> , 2017, 19, 54.	2.2	27
40	The mammography screening debate: time to move on. <i>Lancet</i> , The, 2002, 359, 904-905.	6.3	26
41	OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline <i>BRCA1/2</i> mutations and high-risk HER2-negative early breast cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, LBA1-LBA1.	0.8	26
42	The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32. <i>Journal of the National Cancer Institute</i> , 2021, 113, 192-198.	3.0	24
43	HER-2/neu Overexpression Increases the Viable Hypoxic Cell Population within Solid Tumors without Causing Changes in Tumor Vascularization. <i>Molecular Cancer Research</i> , 2004, 2, 606-619.	1.5	24
44	Lapatinib for breast cancer: a review of the current literature. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 109-121.	1.0	23
45	Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars. <i>Drugs</i> , 2020, 80, 1811-1830.	4.9	23
46	Outcome Definition Influences the Relationship between Genetic Polymorphisms of ERCC1, ERCC2, SLC22A2 and Cisplatin Nephrotoxicity in Adult Testicular Cancer Patients. <i>Genes</i> , 2019, 10, 364.	1.0	21
47	Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2. <i>Clinical Breast Cancer</i> . 2020, 20, e173-e180.	1.1	21
48	Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 1203.	3.4	19
49	Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis. <i>European Journal of Cancer</i> , 2021, 152, 68-77.	1.3	18
50	Cost-effectiveness of annual versus biennial screening mammography for women with high mammographic breast density. <i>Journal of Medical Screening</i> , 2014, 21, 180-188.	1.1	17
51	Optimal Management of Early and Advanced HER2 Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 76-92.	1.8	17
52	Differential expression and prognostic relevance of autophagy-related markers ATG4B, GABARAP, and LC3B in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 525-547.	1.1	17
53	Olaparib tablets for the treatment of germ line BRCA-mutated metastatic breast cancer. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 833-839.	1.3	16
54	Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial. <i>Npj Breast Cancer</i> , 2021, 7, 74.	2.3	16

#	ARTICLE	IF	CITATIONS
55	Osteoblastic metastases from breast carcinoma with false-negative bone scan. <i>Skeletal Radiology</i> , 1997, 26, 434-437.	1.2	13
56	Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab). <i>Breast Cancer Research and Treatment</i> , 2017, 164, 571-580.	1.1	13
57	Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27. <i>Clinical Breast Cancer</i> , 2018, 18, 78-87.	1.1	13
58	Efficacy and safety of palbociclib in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with preexisting conditions: A post hoc analysis of PALOMA-2. <i>Breast</i> , 2021, 59, 321-326.	0.9	13
59	Treatment Beyond Progression: Is It Moving from Belief to Evidence?. <i>Oncologist</i> , 2010, 15, 796-798.	1.9	11
60	Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 343-349.	1.1	11
61	Breast Cancer Subtype Variation by Race and Ethnicity in a Diverse Population in British Columbia. <i>Clinical Breast Cancer</i> , 2016, 16, e49-e55.	1.1	11
62	Novel Therapies for the Treatment of HER2-Positive Advanced Breast Cancer: A Canadian Perspective. <i>Current Oncology</i> , 2022, 29, 2720-2734.	0.9	9
63	Low grade serous carcinoma of the peritoneum in a BRCA1 carrier previously diagnosed with a low-grade serous tubal intra-epithelial carcinoma (STIC) on risk reducing surgery. <i>Gynecologic Oncology Reports</i> , 2015, 12, 72-74.	0.3	8
64	Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. <i>Breast Journal</i> , 2020, 26, 368-375.	0.4	8
65	Impact of the 21-Gene Recurrence Score Assay on the Treatment of Estrogen Receptor-Positive, HER2-Negative, Breast Cancer Patients With 1-3 Positive Nodes: A Prospective Clinical Utility Study. <i>Clinical Breast Cancer</i> , 2022, 22, e74-e79.	1.1	8
66	A phase I study of T900607 given once every 3 weeks in patients with advanced refractory cancers; National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) IND 130. <i>Investigational New Drugs</i> , 2005, 23, 445-453.	1.2	6
67	Establishing a Framework for the Clinical Translation of Germline Findings in Precision Oncology. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa045.	1.4	6
68	Part II: Milestones in personalised medicine—trastuzumab. <i>Lancet Oncology</i> , The, 2008, 9, 698.	5.1	5
69	Willingness of breast cancer patients to undergo biopsy and breast cancer clinicians' practices around seeking biopsy at the time of breast cancer relapse. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 221-228.	1.1	5
70	Cancer Antigen 15-3/Mucin 1 Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs Placebo. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab066.	1.4	5
71	Preliminary efficacy data of triple-negative breast cancer cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 1077-1077.	0.8	5
72	Complementary Medicine Use Amongst Patients with Metastatic Cancer Enrolled in Phase III Clinical Trials. <i>Oncologist</i> , 2022, 27, e286-e293.	1.9	4

#	ARTICLE	IF	CITATIONS
73	Prospective Long-Term Follow-Up of Pulmonary Diffusion Capacity Reduction Caused by Dose-Dense Chemotherapy in Patients with Breast Cancer. <i>Journal of Oncology</i> , 2019, 2019, 1-7.	0.6	3
74	Sotorasib: Is Maximum Tolerated Dose Really the Issue at Hand?. <i>Journal of Clinical Oncology</i> , 2021, 39, 3427-3429.	0.8	3
75	Palbociclib combined with endocrine treatment in breast cancer patients with high relapse risk after neoadjuvant chemotherapy: Subgroup analyses of premenopausal patients in PENELOPE-B.. <i>Journal of Clinical Oncology</i> , 2021, 39, 518-518.	0.8	2
76	Real-world clinical effectiveness and safety of olaparib monotherapy in HER2-negative gBRCA-mutated metastatic breast cancer: Phase IIIb LUCY interim analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1087-1087.	0.8	2
77	Acknowledging Disparities in Hereditary Cancer Testing. <i>Journal of Clinical Oncology</i> , 2021, 39, 4001-4003.	0.8	2
78	Use of Neoadjuvant Platinum—The Ongoing Conundrum. <i>JAMA Oncology</i> , 2017, 3, 1312.	3.4	1
79	Management of adverse events in patients with HER2+ metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine (HER2CLIMB).. <i>Journal of Clinical Oncology</i> , 2020, 38, 1043-1043.	0.8	1
80	Association Between Regional Nodal Irradiation and Breast Cancer Recurrence-Free Interval for Patients With Low-Risk, Node-Positive Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 861-869.	0.4	1
81	Novel Therapies for Metastatic HER2 Positive Breast Cancer. <i>Current Breast Cancer Reports</i> , 2013, 5, 331-340.	0.5	0
82	The Long and Winding Road. <i>Journal of Clinical Oncology</i> , 2015, 33, 229-231.	0.8	0
83	Getting under the skin. <i>European Journal of Cancer</i> , 2017, 82, 228-229.	1.3	0
84	Can We Hang Our Hats on One Percent?. <i>Oncologist</i> , 2018, 23, 642-644.	1.9	0
85	Patient selection for a developmental therapeutics program using whole genome and Transcriptome analysis. <i>Investigational New Drugs</i> , 2020, 38, 1601-1604.	1.2	0
86	Expert Discussion: ASCO 2021. <i>Breast Care</i> , 2021, 16, 429-432.	0.8	0
87	Real-world outcomes of neoadjuvant treatment for HER2 positive early-stage breast cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, e18791-e18791.	0.8	0
88	A Phase I Study of OMN54 (Aneustata, Ⓢ) in Patients with Advanced Malignancies. <i>Clinical Cancer Drugs</i> , 2020, 7, 125-132.	0.3	0
89	Metformin, placebo, and endocrine therapy discontinuation among participants in a randomized double-blind trial of metformin versus placebo in hormone receptor—positive early-stage breast cancer (CCTG MA32).. <i>Journal of Clinical Oncology</i> , 2022, 40, 526-526.	0.8	0